AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Genfit S.a.
Video analysis: GNFTF
All videosNo video analysis for this stock yet. Request one from our team.
News: GNFTF
Genfit S.A. (GNFTF) Discusses Developments and Guidance in MASH Diagnostics Transcript
Genfit S.A. (GNFTF) Discusses Developments and Guidance in MASH Diagnostics Transcript
GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma
Investigational drug GNS561 showed a favorable safety and tolerability profile in a Phase 1b study evaluating its potential in combination with a MEK inhibitor (MEKi) Study conducted in a heavily pretreated, high-unmet-need population of KRAS-mutated cholangiocarcinoma (CCA) patients who had progressed after one or two failed lines of prior standard-of-care therapy Phase 2 initiation on track for initiation in 2H26 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 23, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced positive Phase 1b results for GNS561 in combination therapy in patients with heavily pretreated cholangiocarcinoma, demonstrating a favorable safety and tolerability profile and early signs of antitumor activity. Clinical trial context and objective CCA is a rare and aggressive bile duct cancer, often diagnosed at an advanced stage.
GENFIT: June 15, 2026 Combined Shareholders Meeting Results
All resolutions recommended by the Board of Directors approved (quorum: 32.13 %) Lille (France); Cambridge, ( Massachusetts, United States); Zurich (Switzerland); June 15, 2026 - GENFIT (Euronext: GNFT),, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 15, 2026. The quorum on first convening amounted to 32.13 % and shareholders approved all of the resolutions, with the exception of resolution n°26 which was rejected in accordance with the recommendations of the Board of Directors.
Similar companies
-
Santhera Pharmaceuticals Holding AG
SPHDF
·
Other OTC
Compare
-
JW (Cayman) Therapeutics Co. Ltd
JWCTF
·
Other OTC
Compare
-
Brii Biosciences Limited
BRIBF
·
Other OTC
Compare
-
NDT Pharmaceuticals Inc.
NDTP
·
Other OTC
Compare
-
Silence Therapeutics plc
SLNCF
·
Other OTC
Compare
-
Molecular Partners AG
MLLCF
·
Other OTC
Compare